Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for folic acid
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on folic acid or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on folic acid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Folicacid for fragile X syndrome. It has been argued that individuals with fragile X syndrome could have low folate levels in their bodies and that supplementing their dietary intake might remediate the adverse developmental and behavioural effects of the condition.To review the efficacy and safety of folicacid in the treatment of people with fragile X syndrome.We searched four databases in November 2010: CENTRAL, PubMed, EMBASE and PsycINFO.Randomised controlled trials.Two review authors (...) design. The duration of follow-up ranged from two months to 12 months and the period on folicacid or placebo ranged from two to eight months. Doses of folicacid ranged from 10 mg to 250 mg per day, 10 mg per day being the most common. Most of the younger patients involved were also taking part in special education programmes (usually involving language and occupational therapy).We were not able to perform meta-analysis to combine results but none of the individual studies found evidence of clinical
The mandatory fortification of staple foods with folicacid: a current controversy in Germany. The mandatory fortification of staple foods with folicacid to prevent neural tube defects (NTDs) began in the USA in 1998. Since then, more than 50 countries around the world have followed suit.Selective literature review including national study results.Women of child-bearing age need sufficient body stores of folate before conception to prevent folate-sensitive NTDs, which make up 20% to 60% of all (...) NTDs. Merely recommending folicacid supplementation before conception has been found to be an unsuitable strategy. Ingestion of folate-fortified food markedly increases folate intake, generally by about 50% of the recommended daily total intake. In Germany at present, debate surrounds the issue whether folate intake should be raised by mandatory folate supplementation, which will affect the entire population. Folate deficiency is associated with a higher risk of cancer and other diseases
Folicacid supplementation prevents phenytoin-induced gingival overgrowth in children Gingival overgrowth is an important adverse effect of phenytoin (PHT) therapy, occurring in about half of the patients. This study aimed to evaluate the effect of oral folicacid supplementation (0.5 mg/day) for the prevention of PHT-induced gingival overgrowth (PIGO) in children with epilepsy aged 6-15 years on PHT monotherapy for 6 months.This was a randomized, double-blind, placebo-controlled trial (...) conducted at a tertiary level hospital from May 2008 to June 2009. Children aged 6-15 years started on PHT monotherapy within last 1 month were eligible for inclusion. Preexisting gingival overgrowth, use of other folicacid antagonists, and macrocytic anemia were exclusion criteria. Trial subjects were randomized to receive either folicacid or placebo. The primary outcome measure was incidence of any degree of gingival overgrowth after 6 months of PHT monotherapy. The trial was registered
The effect of folicacid, protein energy and multiple micronutrient supplements in pregnancy on stillbirths. Pregnancy is a state of increased requirement of macro- and micronutrients, and malnourishment or inadequate dietary intake before and during pregnancy, can lead to adverse perinatal outcomes including stillbirths. Many nutritional interventions have been proposed during pregnancy according to the nutritional status of the mother and baseline risk factors for different gestational (...) disorders. In this paper, we have reviewed three nutritional interventions including peri-conceptional folicacid supplementation, balanced protein energy supplementation and multiple micronutrients supplementation during pregnancy. This paper is a part of a series to estimate the effect of interventions on stillbirths for input to Live Saved Tool (LiST) model.We systematically reviewed all published literature to identify studies evaluating effectiveness of peri-conceptional folicacid supplementation
Intermittent iron and folicacid supplementation in menstruating women WHO | Intermittent iron and folicacid supplementation in menstruating women WHO Regional websites Access Nutrition Menu Intermittent iron and folicacid supplementation in menstruating women Guideline Authors : World Health Organization Publication details Number of pages : 30 Publication date : 2011 Languages : Chinese, English, Farsi, French, Portuguese, Russian, Spanish ISBN : 978 92 4 150202 3 Downloads pdf, 1.24Mb pdf (...) , 661.67kb pdf, 762.61kb Overview This guideline provides global, evidence-informed, recommendations on the intermittent use of iron and folicacid supplements as a public health measure for the purpose of reducing anaemia and improving iron status among menstruating women. The guideline will help Members States and their partners in their efforts to make informed decisions on the appropriate nutrition actions to achieve the Millennium Development Goals, in particular, promotion of gender equality
Folicacid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis. The efficacy of folicacid therapy to lower homocysteine (Hcy) levels in an effort to reduce cardiovascular disease (CVD) risk in patients with ESRD or advanced chronic kidney disease (ACKD; creatinine clearance, <30 ml/min) remains inconclusive. We conducted a meta-analysis of relevant randomized trials to further examine this issue.This meta-analysis included 3886 patients with ESRD/ACKD (...) from seven qualified randomized trials using folicacid therapy and with CVD reported as one of the end points.When pooling the seven trials, folicacid therapy reduced the risk of CVD by 15% (RR, 0.85; 95% CI, 0.76 to 0.96; P = 0.009). A greater beneficial effect was observed among those trials with a treatment duration >24 months (RR, 0.84; 95% CI, 0.72 to 0.98; P = 0.02), a decrease in Hcy level >20% (RR, 0.83; 95% CI, 0.73 to 0.95; P = 0.007), and no or partial folicacid fortification (RR
Folicacid supplementation and colorectal cancer risk: a meta-analysis. This meta-analysis aims to determine the effect of folicacid supplementation on colorectal cancer risk.A structured search of the MEDLINE, EMBASE, Cochrane and CINAHL databases was undertaken in July 2008. All published full text English language articles were searched that included a randomized or pseudo-randomized comparison of subjects who received folate vs subjects who did not in relation to their risk of adenoma
Effect of folicacid supplementation on cardiovascular outcomes: a systematic review and meta-analysis. Folicacid is widely used to lower homocysteine concentrations and prevent adverse cardiovascular outcomes. However, the effect of folicacid on cardiovascular events is not clear at the present time. We carried out a comprehensive systematic review and meta-analysis to assess the effects of folicacid supplementation on cardiovascular outcomes.We systematically searched Medline, EmBase (...) , the Cochrane Central Register of Controlled Trials, reference lists of articles, and proceedings of major meetings for relevant literature. We included randomized placebo-controlled trials that reported on the effects of folicacid on cardiovascular events compared to placebo. Of 1594 identified studies, we included 16 trials reporting data on 44841 patients. These studies reported 8238 major cardiovascular events, 2001 strokes, 2917 myocardial infarctions, and 6314 deaths. Folicacid supplementation
Meta analysis suggests that folicacid supplementation does not reduce risk of stroke, but there may be some benefit when given in combination with vitamins B6 and B12 and in primary prevention. 20797992 2010 12 27 2012 02 09 1473-6810 15 6 2010 Dec Evidence-based medicine Evid Based Med Meta analysis suggests that folicacid supplementation does not reduce risk of stroke, but there may be some benefit when given in combination with vitamins B6 and B12 and in primary prevention. 168-70 10.1136
Vitamins B(12), B(6), and folicacid for cognition in older men To investigate whether supplementing older men with vitamins B(12), B(6), and folicacid improves cognitive function.The investigators recruited 299 community-representative hypertensive men 75 years and older to a randomized, double-blind controlled clinical trial of folicacid, vitamin B(6), and B(12) supplementation vs placebo over 2 years. The primary outcome of interest was the change in the cognitive subscale (...) , p = 0.478). There was a nonsignificant 28% decrease in the risk of cognitive impairment (odds ratio 0.72, 95% confidence interval 0.25-2.09) and dementia (hazard ratio 0.72, 95% confidence interval 0.29-1.78) over 8 years of follow-up.The daily supplementation of vitamins B(12), B(6), and folicacid does not benefit cognitive function in older men, nor does it reduce the risk of cognitive impairment or dementia.This study provides Class I evidence that vitamin supplementation with daily doses
Mental health literacy, folicacid and vitamin B12, and physical activity for the prevention of depression in older adults: randomised controlled trial Few randomised controlled trials (RCTs) have examined potential preventive agents in high-risk community populations.To determine whether a mental health literacy intervention, the promotion of physical activity, or folicacid plus vitamin B(12) reduce depression symptoms in community-dwelling older adults with elevated psychological distress.An (...) RCT with a completely crossed 2 x 2 x 2 factorial design: (400 mcg/d folicacid + 100 mcg/d vitamin B(12) v. placebo)x(physical activity v. nutrition promotion control)x(mental health literacy v. pain information control). The initial target sample size was 2000; however, only 909 adults (60-74 years) met the study criteria. Interventions were delivered by mail with telephone calls. The main outcome was depressive symptoms on the Patient Health Questionnaire (PHQ-9) at 6 weeks, 6, 12 and 24 months
Effect of folicacid, with or without other B vitamins, on cognitive decline: meta-analysis of randomized trials We aimed to quantify the effect of folicacid supplementation on the prevention of cognitive decline.We conducted a meta-analysis of 9 placebo-controlled randomized trials (2835 participants, median duration 6 months) of folicacid, with or without other B vitamins, on cognitive function. Standardized mean differences in cognitive function test scores were calculated between folic (...) , -0.13 to 0.19), respectively.Randomized trials show no effect of folicacid, with or without other B vitamins, on cognitive function within 3 years of the start of treatment. Trials of longer duration, recording the incidence of dementia, as well as cognitive decline, are needed.Copyright 2010 Elsevier Inc. All rights reserved.
Efficacy of homocysteine-lowering therapy with folicAcid in stroke prevention: a meta-analysis Although a lower serum homocysteine concentration is associated with a reduced risk of stroke in epidemiologic studies, randomized, controlled trials have yielded mixed findings regarding the effect of therapeutic homocysteine lowering on stroke prevention. We performed a meta-analysis of randomized, controlled trials to assess the efficacy of folicacid supplementation in the prevention (...) of stroke.Salient trials were identified by formal literature search. Relative risk (RR) with 95% CI was used as a measure of the association between folicacid supplementation and risk of stroke, after pooling data across trials in a fixed-effects model.The search identified 13 randomized, controlled trials that had enrolled 39 005 participants for folicacid therapy to reduce homocysteine in which stroke was reported as an outcome measure. Across all trials, folicacid supplementation was associated
[Meta-analysis of effect of intervention with folicacid on neural tube defects]. To provide evidences for decision-making on neural tube defects prevention according to evaluating the effect of intervention with 0.4 mg folicacid on the incidence of neural tube defects in China.Meta-analysis with software of Review Manager 4.2 version was used to synthetically and quantitatively evaluate the studies included. The Peto method of fixed effect model and random effect model (DerSimonin and Laird (...) ) were applied to estimate combined effect values and their corresponding 95% confidence intervals of homogenous and inhomogenous data respectively.Six pieces of literature included in which the studies were folicacid intervention were inhomogenous (chi2 = 13.43, P = 0. 02). Random effect model of Meta-analysis method were used. The combined effect values of intervention with folicacid on neural tube defects among women were strikingly significance (Z = 5.17, P = 0.00001). The pooled RR values were
Effects of homocysteine-lowering with folicacid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. Blood homocysteine levels are positively associated with cardiovascular disease, but it is uncertain whether the association is causal.To assess the effects of reducing homocysteine levels with folicacid and vitamin B(12) on vascular and nonvascular outcomes.Double-blind randomized controlled trial of 12,064 survivors (...) of myocardial infarction in secondary care hospitals in the United Kingdom between 1998 and 2008.2 mg folicacid plus 1 mg vitamin B(12) daily vs matching placebo.First major vascular event, defined as major coronary event (coronary death, myocardial infarction, or coronary revascularization), fatal or nonfatal stroke, or noncoronary revascularization.Allocation to the study vitamins reduced homocysteine by a mean of 3.8 micromol/L (28%). During 6.7 years of follow-up, major vascular events occurred in 1537
Folicacid to reduce neonatal mortality from neural tube disorders Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Meta-analysis: folicacid in the chemoprevention of colorectal adenomas and colorectal cancer Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Meta-analysis of folicacid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
[Effects of folicacid supplementation on pregnancy outcomes: a review of randomized clinical trials]. Despite the causal association between defects of the metabolism of the folate (hyperhomocysteinemia) and risk of neural tube defects are both well documented, the association between folate deficiency and other pregnancy pathologies is still not entirely clear. The present article aims to gather the data published about the relationship between serum folate and pregnancy pathologies (...) with folate supplementation versus placebo. In the clinical studies where folicacid (FA) could improve pregnancy outcomes, its effect was not statistically significant, except for three studies where FA showed a significant decrease of low birthweight. With regard to preterm birth, pre-eclampsia and abruptio placentae, although in some observational studies AF was found to be associated with a reduction of these adverse outcomes, in currently available controlled clinical trials, FA supplementation had